|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma.
|
31610171 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
|
31804622 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a type of T-cell lymphoma that can be divided into two categories: anaplastic lymphoma kinase-positive (ALK+) and ALK-negative.Gastrointestinal ALK+ ALCL is rare.
|
31423437 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we used a systemic NPM-ALK<sup>+</sup> T cell lymphoma mouse model to analyze the in vivo effects of PPP and ASP3026 alone or in combination.
|
31340850 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, this is the first reported case of primary gastric ALK-negative and EBV-negative anaplastic large T-cell lymphoma that presented without gastroenterological symptoms.
|
28652442 |
2018 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BI-ALCL is an anaplastic lymphoma kinase-negative T-cell lymphoma that has a distinctively different clinical course than other breast lymphomas or ALCLs.
|
28625797 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>ALK</i> was first identified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ ALCL), the vast majority of which harbor the well-characterized nucleophosmin (NPM)-ALK fusion protein.
|
27879258 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK<sup>+</sup> ) T-cell lymphoma is an aggressive neoplasm that is more commonly seen in children and young adults.
|
28557340 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we found that the SUMOylation pathway is deregulated in NPM-ALK+ T-cell lymphoma cell lines and primary lymphoma tumors from patients.
|
26476082 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Is ALK-gene rearrangement overlooked in primary gastrointestinal T-cell lymphomas? About two cases.
|
26531107 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPM-ALK(+) T-cell lymphoma exhibits much higher levels of IGF-IR than normal human T lymphocytes.
|
25884514 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the basis of an index case of CD4 S100 T-cell prolymphocytic leukemia (T-PLL), we studied S100 protein expression in 19 additional T-PLLs and 56 other T-cell lymphomas that are usually CD4, including 15 angioimmunoblastic T-cell lymphomas, 24 anaplastic large cell lymphomas (16 ALK and 8 ALK), 7 mycosis fungoides/Sézary syndrome, and 10 peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS).
|
26379148 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is an aggressive T-cell non-Hodgkin lymphoma characterized by the t(2;5), resulting in the overexpression of nucleophosmin (NPM)-ALK, which is known to activate the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, resulting in cell cycle and apoptosis deregulation.
|
25987255 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a distinct entity of T-cell lymphoma that can be divided into 2 subtypes based on the presence of translocations involving the ALK gene (ALK(+) and ALK(-) ALCL).
|
25359993 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive T-cell non-Hodgkin lymphoma that morphologically resembles ALK-positive ALCL but lacks chromosomal rearrangements of the ALK gene.
|
24894770 |
2014 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systemic anaplastic large cell lymphoma is a category of T-cell non-Hodgkin's lymphoma which can be further subdivided into two distinct entities (ALK(+) and ALK(-)) based on the presence or absence of ALK gene rearrangements.
|
23975180 |
2014 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested the hypothesis that iNOS is deregulated in NPM-ALK(+) T-cell lymphoma and promotes the survival of this lymphoma.
|
23338972 |
2013 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In both ALK(+) TCL and IL-2-stimulated ALK(-) TCL cells, CD25, SOCS3, and Irf-4 genes were activated predominantly by the STAT5 and STAT3 transcription factors, whereas transcription of Egr-1 and Fosl-1 was induced by the MEK-ERK pathway.
|
24218456 |
2013 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) is a T cell lymphoma defined by the presence of chromosomal translocations involving the ALK tyrosine kinase gene.
|
22681779 |
2012 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, the prognosis of ALK+ ALCL is remarkably better than other T-cell lymphomas.
|
22440390 |
2012 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results also provide another rationale to therapeutically target NPM/ALK and STAT3 in ALK+ TCL.
|
21102525 |
2011 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene expression profiling (GEP) was performed in a series of systemic primary T-NHL (n = 70), including a set of ALK-positive and ALK-negative ALCL (n = 36).
|
20159827 |
2010 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a main type of T-cell lymphomas and comprises three distinct entities: systemic anaplastic lymphoma kinase (ALK) positive, systemic ALK(-) and cutaneous ALK(-) ALCL (cALCL).
|
19657361 |
2009 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique type of T-cell lymphoma.
|
19423729 |
2009 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, within this heterogenous group of neoplasms, some have a more favorable prognosis, such as ALK-positive anaplastic large-cell leukemia (ALCL) and primary cutaneous ALCL, and some have ultimately fatal courses with standard chemotherapy programs (e.g., hepatosplenic gammadelta T-cell lymphomas).
|
19074097 |
2008 |